Article Sidebar

pdf
Date Published: 25/09/2023
Abstract Views: 217
Views pdf: 106
DOI: https://doi.org/10.51298/vmj.v530i1B.6702
Issue
Vol. 530 No. 1B (2023)
Section
Các bài báo
How to Cite
Đỗ, A. T., & Dương, T. L. (2023). STUDYING ON SURVIVAL TIME OF PATIENTS WITH TESTICULAR ESISTANT PROSTATE CANCER AFTER CHEMOTHERAPY ACCORDING TO DOCETAXEL - PREDNISOLONE REGIMEN. Vietnam Medical Journal, 530(1B). https://doi.org/10.51298/vmj.v530i1B.6702

STUDYING ON SURVIVAL TIME OF PATIENTS WITH TESTICULAR ESISTANT PROSTATE CANCER AFTER CHEMOTHERAPY ACCORDING TO DOCETAXEL - PREDNISOLONE REGIMEN

Anh Tú Đỗ1,, Thị Lệ Dương2
1 K Hospital
2 HMU

Main Article Content

Abstract

Background: Prostate cancer is the second most common cancer in men. Although initial response rates to ADT are as high as 80 to 90%, virtually all patients eventually progress to testicular resistance at 18-24 months. Purpose: To Analysis of survival time of patients with orchiectomy-resistant prostate cancer treated with Docetaxel-Prednisolone regimen at K Hospital and some influencing factors. Methods: Evaluation of survival time of 38 patients with testicular resistant prostate cancer treated with Docetaxel-Prednisolone regimen. Results: Median PFS of patients with ADT response ≥ 12 months was 6.4 months compared with 6,3 months in the ADT response curve < 12 months, p = 0,598. Median PFS in patients with visceral metastasis was 4,6 months compared with 6,8 months in the group without visceral metastasis, p = 0,029. Conclusion: Median progression-free survival was significantly higher in patients treated with 8 or more cycles of chemotherapy and no visceral metastases.

Article Details

Keywords

Prostatic cancer, Survival, anti-testis.

References

1. I. F. Tannock, et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 2004. 351(15): p. 1502-12.
2. D. P. Petrylak, et al., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 2004. 351(15): p. 1513-20.
3. S. Naito, et al., Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol, 2008. 38(5): p. 365-72.
4. F. Y. Cheung, K. C. Leung, and R. K. Ngan, Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer. Hong Kong Med J, 2013. 19(3): p. 237-41.
5. G. R. Pond, et al., The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol, 2014. 65(1): p. 3-6.
6. E. S. de Morree, et al., Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study. JAMA Oncol, 2017. 3(1): p. 68-75.
7. E. A. Benaim, C. M. Pace, and C. G. Roehrborn, Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urol, 2002. 42(1): p. 12-7.